A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease

Annals of Neurology

Volumn 76, Issue 2, 2014, Pages 185-205

  Karran, Eric ^a,b,c   Hardy, John ^b,c  

^a Alzheimer's Research UK   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID PRECURSOR PROTEIN; BAPINEUZUMAB; HOMOTAURINE; IMMUNOGLOBULIN G; PLACEBO; PRESENILIN 1; PRESENILIN 2; SEMAGACESTAT; SOLANEZUMAB; TARENFLURBIL;

ALZHEIMER DISEASE; AUTOSOMAL DOMINANT INHERITANCE; CLINICAL FEATURE; GENE MUTATION; HUMAN; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; DRUG DEVELOPMENT; PLAQUE, AMYLOID; STANDARDS;

ALZHEIMER DISEASE; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DISCOVERY; HUMANS; PLAQUE, AMYLOID;

EID: 84907597179     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24188     Document Type: Review

References (132)

1. Alzheimer A,. About a peculiar disease of the cerebral cortex. Centralblatt für Nervenheilkunde Psychiatrie 1907; 30: 177-179.
2. Selkoe DJ,. The molecular pathology of Alzheimer's disease. Neuron 1991; 6: 487-498.
3. Hardy JA, Higgins GA,. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256: 184-185.
4. Glenner GG, Wong CW,. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984; 122: 1131-1135.
5. Ott A, Breteler MM, van Harskamp F, et al. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ 1995; 310: 970-973.
6. Gomez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997; 41: 17-24.
7. McLean CA, Cherny RA, Fraser FW, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999; 46: 860-866.
8. McDonald JM, Savva GM, Brayne C, et al. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 2010; 133 (pt 5): 1328-1341.
9. Karran E, Mercken M, De Strooper B,. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011; 10: 698-712.
10. Braak H, Braak E,. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
11. Mitchell TW, Mufson EJ, Schneider JA, et al. Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease. Ann Neurol 2002; 51: 182-189.
12. Savva GM, Wharton SB, Ince PG, et al. Age, neuropathology, and dementia. N Engl J Med 2009; 360: 2302-2309.
13. Castillo GM, Lukito W, Wight TN, Snow AD,. The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation. J Neurochem 1999; 72: 1681-1687.
14. Snow AD, Sekiguchi R, Nochlin D, et al. An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain. Neuron 1994; 12: 219-234.
15. Gervais F, Chalifour R, Garceau D, et al. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid 2001; 8 (suppl 1): 28-35.
16. Gervais F, Paquette J, Morissette C, et al. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 2007; 28: 537-547.
17. Martineau E, de Guzmann JM, Rodionova L, et al. Investigation of the noncovalent interactions between anti-amyloid agents and amyloid beta peptides by ESI-MS. J Am Mass Spectrom 2010; 21: 9.
18. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-413.
19. Guo JP, Yu S, McGeer PL,. Simple in vitro assays to identify amyloid-beta aggregation blockers for Alzheimer's disease therapy. J Alzheimers Dis 2010; 19: 1359-1370.
20. Fawver JN, Duong KT, Wise-Scira O, et al. Probing and trapping a sensitive conformation: amyloid-beta fribrils, oligomers, and dimers. J Alzheimers Dis 2012; 32: 19.
21. Aisen PS, Saumier D, Briand R, et al. A phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 2006; 67: 1757-1763.
22. Fukuyama R, Mizuno T, Mori S, et al. Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients. Eur Neurol 2000; 43: 155-160.
23. Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999; 56: 673-680.
24. Roe CM, Fagan AM, Grant EA, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 2013; 80: 1784-1791.
25. Aisen PS, Gauthier S, Ferris SH, et al. Tramiprosate in mild-to-moderate Alzheimer's disease-a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci 2011; 7: 102-111.
26. McGeer PL, Schulzer M, McGeer EG,. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996; 47: 425-432.
27. in 't Veld BA, Launer LJ, Hoes AW, et al. NSAIDs and incident Alzheimer's disease. The Rotterdam Study. Neurobiol Aging 1998; 19: 607-611.
28. in t' Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345: 1515-1521.
29. Arvanitakis Z, Grodstein F, Bienias JL, et al. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 2008; 70: 2219-2225.
30. Breitner JC, Haneuse SJ, Walker R, et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 2009; 72: 1899-1905.
31. Sonnen JA, Larson EB, Walker RL, et al. Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Neurology 2010; 75: 1203-1210.
32. Jaturapatporn D, Isaac MG, McCleery J, Tabet N,. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2012; 2: CD006378.
33. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001; 414: 212-216.
34. De Strooper B, Annaert W, Cupers P, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999; 398: 518-522.
35. Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. J Clin Invest 2003; 112: 440-449.
36. Kukar TL, Ladd TB, Bann MA, et al. Substrate-targeting gamma-secretase modulators. Nature 2008; 453: 925-929.
37. Beel AJ, Barrett P, Schnier PD, et al. Nonspecificity of binding of gamma-secretase modulators to the amyloid precursor protein. Biochemistry 2009; 48: 11837-11839.
38. Barrett PJ, Sanders CR, Kaufman SA, et al. NSAID-based gamma-secretase modulators do not bind to the amyloid-beta polypeptide. Biochemistry 2011; 50: 10328-10342.
39. Beher D, Clarke EE, Wrigley JD, et al. Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J Biol Chem 2004; 279: 43419-43426.
40. Borgegard T, Jureus A, Olsson F, et al. First and second generation gamma-secretase modulators (GSMs) modulate amyloid-beta (Abeta) peptide production through different mechanisms. J Biol Chem 2012; 287: 11810-11819.
41. Imbimbo BP, Del Giudice E, Cenacchi V, et al. In vitro and in vivo profiling of CHF5022 and CHF5074 two beta-amyloid1-42 lowering agents. Pharmacol Res 2007; 55: 318-328.
42. Peretto I, Radaelli S, Parini C, et al. Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion. J Med Chem 2005; 48: 5705-5720.
43. Kukar T, Prescott S, Eriksen JL, et al. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci 2007; 8: 54.
44. Lanz TA, Fici GJ, Merchant KM,. Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. J Pharmacol Exp Ther 2005; 312: 399-406.
45. Galasko DR, Graff-Radford N, May S, et al. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord 2007; 21: 292-299.
46. Wilcock GK, Black SE, Hendrix SB, et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 2008; 7: 483-493.
47. Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009; 302: 2557-2564.
48. De Strooper B, Saftig P, Craessaerts K, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998; 391: 387-390.
49. Wolfe MS, Xia W, Ostaszewski BL, et al. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 1999; 398: 513-517.
50. Wolfe MS,. γ-Secretase inhibitors and modulators for Alzheimer's disease. J Neurochem 2012; 120 (suppl 1): 89-98.
51. De Strooper B,. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev 2010; 90: 465-494.
52. Kopan R, Ilagan MX,. Gamma-secretase: proteasome of the membrane? Nat Rev Mol Cell Biol 2004; 5: 499-504.
53. Gillman KW, Starrett JEJ, Parker MF, et al. Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable γ-secretase inhibitor. Med Chem Lett 2010; 1: 120-124.
54. Brodney MA, Auperin DD, Becker SL, et al. Design, synthesis, and in vivo characterization of a novel series of tetralin amino imidazoles as gamma-secretase inhibitors: discovery of PF-3084014. Bioorg Med Chem Lett 2011; 21: 2637-2640.
55. Martone RL, Zhou H, Atchison K, et al. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther 2009; 331: 598-608.
56. Gitter B, Czilli DL, Li W, et al. Stereoselective inhibition of amyloid beta peptide secretion by LY450139, a novel functional gamma secretase inhibitor. Neurobiol Aging 2004; 25 (suppl 2): 1.
57. Mitani Y, Yarimizu J, Saita K, et al. Differential effects between gamma-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci 2012; 32: 2037-2050.
58. Li T, Huang Y, Jin S, et al. Gamma-secretase modulators do not induce Abeta-rebound and accumulation of beta-C-terminal fragment. J Neurochem 2012; 121: 277-286.
59. Chavez-Gutierrez L, Bammens L, Benilova I, et al. The mechanism of γ-secretase dysfunction in familial Alzheimer disease. EMBO J 2012; 31: 2261-2274.
60. Burton CR, Meredith JE, Barten DM, et al. The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expression. J Biol Chem 2008; 283: 22992-23003.
61. Lanz TA, Karmilowicz MJ, Wood KM, et al. Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. J Pharmacol Exp Ther 2006; 319: 924-933.
62. May PC, Yang Z, Li W, et al. Multi-compartmental pharmaco-dynamic assessment of the functional gamma-secretase inhibitor LY450139 dihydrate in PDAPP transgenic mice and non-transgenic mice. Neurobiol Aging 2004; 25 (suppl 2): 1.
63. Hyslop PA, May PC, Audia JE, et al. Reduction in A-beta (1-40) and A-beta (1-42) in CSF and plasma in the beagle dog following acute oral dosing of the gamma secretase inhibitor, LY450139. Neurobiol Aging 2004; 25 (suppl 2): 1.
64. Henley DB, May PC, Dean RA, Siemers ER,. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. Expert Opin Pharmacother 2009; 10: 1657-1664.
65. Bateman RJ, Munsell LY, Morris JC, et al. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 2006; 12: 856-861.
66. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995; 373: 523-527; comments 1995;373:476-477, 1995;375:285.
67. Boggs LN, Fuson KS, Gitter B, et al. In vivo characterization of LY450139, a novel, stereoselective, functional gamma secretase inhibitor. Neurobiol Aging 2004; 25 (suppl 2): 1.
68. Ness D, Boggs LN, Hepburn DL, et al. Reduced beta-amyloid burden, increased C99 concentrations and evaluation of neuropathology in the brains of PDAPP mice given LY450139 dihydrate daily by gavage for 5 months. Neurobiol Aging 2004; 25 (suppl 2): 1.
69. Abramowski D, Wiederhold KH, Furrer U, et al. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther 2008; 327: 411-424.
70. Yan P, Bero AW, Cirrito JR, et al. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci 2009; 29: 10706-10714.
71. Garcia-Alloza M, Subramanian M, Thyssen D, et al. Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575. Mol Neurodegener 2009; 4: 19.
72. Das P, Verbeeck C, Minter L, et al. Transient pharmacologic lowering of Abeta production prior to deposition results in sustained reduction of amyloid plaque pathology. Mol Neurodegener 2012; 7: 39.
73. Siemers E, Skinner M, Dean RA, et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol 2005; 28: 126-132.
74. Siemers ER, Quinn JF, Kaye J, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 2006; 66: 602-604.
75. Siemers ER, Dean RA, Friedrich S, et al. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol 2007; 30: 317-325.
76. Bateman RJ, Siemers ER, Mawuenyega KG, et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 2009; 66: 48-54.
77. Fleisher AS, Raman R, Siemers ER, et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008; 65: 1031-1038.
78. Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 2013; 369: 341-350.
79. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-177.
80. Solomon B, Koppel R, Frankel D, Hanan-Aharon E,. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A 1997; 94: 4109-4112.
81. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408: 982-985.
82. Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000; 408: 979-982.
83. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61: 46-54.
84. Pride M, Seubert P, Grundman M, et al. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis 2008; 5: 194-196.
85. Zotova E, Holmes C, Johnston D, et al. Microglial alterations in human Alzheimer's disease following Abeta42 immunization. Neuropathol Appl Neurobiol 2011; 37: 513-524.
86. Zotova E, Bharambe V, Cheaveau M, et al. Inflammatory components in human Alzheimer's disease and after active amyloid-beta42 immunization. Brain 2013; 136 (pt 9): 2677-2696.
87. Serrano-Pozo A, William CM, Ferrer I, et al. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain 2010; 133 (pt 5): 1312-1327.
88. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216-223.
89. Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9: 448-452.
90. Ferrer I, Boada Rovira M, Sanchez Guerra ML, et al. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004; 14: 11-20.
91. Masliah E, Hansen L, Adame A, et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005; 64: 129-131.
92. Maarouf CL, Daugs ID, Kokjohn TA, et al. The biochemical aftermath of anti-amyloid immunotherapy. Mol Neurodegener 2010; 5: 39.
93. Patton RL, Kalback WM, Esh CL, et al. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol 2006; 169: 1048-1063.
94. Lee M, Bard F, Johnson-Wood K, et al. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol 2005; 58: 430-435.
95. Johnson-Wood K, Lee M, Motter R, et al. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A 1997; 94: 1550-1555.
96. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916-919.
97. Demattos RB, Lu J, Tang Y, et al. A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer's disease mice. Neuron 2012; 76: 908-920.
98. Miles LA, Crespi GA, Doughty L, Parker MW,. Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. Sci Rep 2013; 3: 1302.
99. Bacskai BJ, Kajdasz ST, McLellan ME, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci 2002; 22: 7873-7878.
100. Legleiter J, Czilli DL, Gitter B, et al. Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. J Mol Biol 2004; 335: 997-1006.
101. Bard F, Fox M, Friedrich S, et al. Sustained levels of antibodies against Abeta in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice. Exp Neurol 2012; 238: 38-43.
102. Racke MM, Boone LI, Hepburn DL, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005; 25: 629-636.
103. Schroeter S, Khan K, Barbour R, et al. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci 2008; 28: 6787-6793.
104. Seubert P, Barbour R, Khan K, et al. Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener Dis 2008; 5: 65-71.
105. Black RS, Sperling RA, Safirstein B, et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2010; 24: 198-203.
106. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009; 73: 2061-2070.
107. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010; 9: 363-372.
108. Blennow K, Zetterberg H, Rinne JO, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 2012; 69: 1002-1010.
109. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014; 370: 322-333.
110. Seubert P, Vigo-Pelfrey C, Esch F, et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluid. Nature 1992; 359: 325-327; comment 268-269.
111. Imbimbo BP, Ottonello S, Frisardi F, et al. Solanezumab for the treatment of mild-to-moderate Alzheimer's disease. Expert Rev Clin Immunol 2012; 8: 135-149.
112. DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2001; 98: 8850-8855.
113. DeMattos RB, Bales KR, Parsadanian M, et al. Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem 2002; 81: 229-236.
114. Siemers ER, Friedrich S, Dean RA, et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2010; 33: 67-73.
115. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014; 370: 311-321.
116. Karran E, Hardy J,. Antiamyloid therapy for Alzheimer's disease-are we on the right road? N Engl J Med 2014; 370: 377-378.
117. Gaskin F, Finley J, Fang Q, et al. Human antibodies reactive with beta-amyloid protein in Alzheimer's disease. J Exp Med 1993; 177: 6.
118. Xu S, Gaskin F,. Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease. Mech Ageing Dev 1997; 94: 10.
119. Du Y, Dodel R, Hampel H, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 2001; 57: 801-805.
120. Dodel R, Hampel H, Depboylu C, et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 2002; 52: 4.
121. Fillit H, Hess G, Hill J, et al. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 2009; 73: 180-185.
122. Du Y, Wei X, Dodel R, et al. Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid induced neurotoxicity. Brain 2003; 126: 51935.
123. O'Nuallain B, Hrncic R, Wall JS, et al. Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. J Immunol 2006; 176: 8.
124. Magga J, Puli L, Pihlaja R, et al. Human intravenous immunoglobulin provides protection against Abeta toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation 2010; 7: 15.
125. Bacher M, Depboylu C, Du Y, et al. Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease. Neurosci Lett 2009; 449: 240-245.
126. Kountouris D,. Therapeutic effects of piracetam combined with intravenous immunoglobulin premature of Alzheimer type. J Neural Transm 2000; 107: 1.
127. Dodel RC, Du Y, Depboylu C, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004; 75: 1472-1474.
128. Relkin NR, Szabo P, Adamiak B, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer's disease. Neurobiol Aging 2009; 30: 9.
129. Dodel R, Rominger A, Bartenstein P, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 2013; 12: 233-243.
130. Mangialasche F, Solomon A, Winblad B, et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010; 9: 702-716.
131. Miller G,. Alzheimer's research. Stopping Alzheimer's before it starts. Science 2012; 337: 790-792.
132. Farlow M, Arnold SE, van Dyck CH, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement 2012; 8: 261-271.